²§Åé©PÃä³y¦å¥ý´Á²ÓM²¾´Ó(allogeneic peripheral blood progenitor cells transplantation)«K¬O§Q¥Î¥Õ ¦å²y¥Íªø¦]¤l(leukocyte growth factors)°Êû (mobilize)¡B¦a¤¤®ü«¬³h¦å(thalassemia)¤Î¦A¥Í¤£ ¨}©Ê³h¦å®½Ãت̰©Åèùتº³y¦å¥ý´Á²ÓM¦Ü©PÃä ¦å²G¤¤¡A¨Ã¥[¥H¦¬¶°¡AµM«á¿éª`¦Ü¨ü®½ªÌªºÅé ¤º¥H««Ø¨ä³y¦å¾÷¯à¡C¦¹ºØ¤èªk¦p¦P¤@¯ë²§Åé °©Åè²¾´Ó(allogeneic bone marrow transplantation ¡A³\¦h¦å²G´c©Ê¯e¯f¡B¥ý¤Ñ©Î«á¤Ñ³y¦å¾÷¯à ²§±`ªÌ¡A¦p¥Õ¦å¯f(leukemia)¡B²O¤Ú½F (lymphoma)¡B¦a¤¤®ü«¬³h¦å(thalassemia)¤Î¦A¥Í ¤£¨}©Ê³h¦å(aplastic anemia)µ¥¬Ò¦³ªv¡ªº®ÄªG¡C °ß¦³¤£¦P³B¬O«eªÌ¤£Y«áªÌ»Ý«_¤â³N¤Î¥þ¨³Â ¾Kªº¦MÀI¡A¦Ó¥un¦p®½¦å¯ë±N©PÃä¦å²G¤¤ªº³y ¦å¥ý´Á²ÓM®½¥X§Y¥i¡A¹ê¿×¤@ºØ¸û¦w¥þ¥B²«K ªº¦¬¶°¤èªk¡C¸gªñ¤T¦~¨Ó¼Ú¬üÁ{§É¬ã¨sÅã¥Ü¡A ¨ä¬Û¸û©ó¶Ç²Î²§Åé°©Åè²¾´Ó¡A¤£¦ý¦w¥þ©Ê¸û°ª ¦Ó¥B¨ü®½ªÌ«ì´_¸û§Ö¡A¥§¡¥un14¤Ñ§Y¥i««Ø ³y¦å¨t²Î¡A³o¨Ï±o¦í°|¤Ñ¼Æ´î¤Ö¨Ã¥B¥i¥H°§C ¦¨¥»¡C¥t¥~¡A¨äªvÀø¦¨®Ä¥ç¬Û·í¡C¦ý«eªÌ¬O¥Ñ ©PÃä¦å²G¦¬¶°¡A¾Ö¦³¸û¦hªºT-²ÓM¤Î¦ÛµM±þ¤â ²ÓM(natural killer cells)¡A¦]¦¹¥i¯à¦³¸û¬°Àu²§ªº ´ÓÅé§Ü¥Õ¦å¯f®ÄªG(graft-versus-leukemia effect GvL)¡AµM¦Ó«æ©Ê´ÓÅé§Ü±J¥D¯e¯f(acute graft-versus-host disease; aGvHD)ªº¤ñ¨Ò«o¨Ã¥¼ÀH ¤§ª@°ª¡C¥Ñ©ó¦¹ªk¦n³B¬Æ¦h¡A©Ò¥H¥¼¨Ó³oºØ²§ Åé©PÃä³y¦å¥ý´Á²ÓM²¾´Ó¥i¯à·|³vº¥¨ú¥N²§Åé °©Åè²¾´Ó¦Ó¦¨¬°¦¹¤@ªvÀøªº¥D¬y¡C |